Patent application number | Description | Published |
20090075932 | METHOD OF SELECTIVELY INHIBITING PKCiota - PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1α,2β,3β,4α)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota. | 03-19-2009 |
20090239850 | Kinase protein binding inhibitors - The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer. | 09-24-2009 |
20090286808 | Opsin Stabilizing Compounds and Methods of Use - The present invention provides compositions and methods useful in the treatment and/or prevention of ophthalmic conditions and diseases, such as retinitis pigmentosa, that are dependent upon or related to misfolded opsin proteins in vivo. In addition, screening assays for agents useful in such treatment methods are described. | 11-19-2009 |
20100035940 | Cyclin Dependent Kinase Inhibitors - The invention relates to cyclin dependent kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer. | 02-11-2010 |
20100076018 | Compounds and Methods for Treatment of Alpha-1 Antitrypsin Deficiency - The invention features compositions and methods that are useful for treating or preventing AAT deficiency and associated conditions. In addition, the invention provides methods for identifying compounds useful for treatment of AAT deficiency and associated conditions. | 03-25-2010 |
20100190702 | Compositions and Methods of Treating Neoplasia - The invention features compositions and methods that are useful for the treatment of neoplasia by reducing base excision repair (BER). Such compositions are useful, for example, for enhancing the efficacy of known chemotherapeutics, such as DNA alkylating agents. In particular, the invention features agents that mimic the interaction of APC with pol-β. Such agents reduce the activity of long patch- and single nucleotide-base extension repair pathways. | 07-29-2010 |
20100285012 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS - The subject application provides small compounds that are able to suppress autophagy in various cells. These compounds are useful in augmenting the existing treatments of various cancers and microbial/parasitic infections. Thus, the subject application also provides methods of treating various types of cancers and microbial/parasitic infections. Also provided by the subject application are methods of suppressing the expansion of autophagosomes within cells or individuals and inhibiting the lipidation of autophagy-related protein 8 (Atg8). | 11-11-2010 |
20110065664 | KINASE PROTEIN BINDING INHIBITORS - The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer. | 03-17-2011 |
20110110958 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOPLASIA - The invention provides compositions and methods for the treatment of neoplasias that are cytotoxic to neoplastic cells or that modulate JAZ expression, subcellular localization, or biological activity. | 05-12-2011 |
20110152206 | THERAPEUTIC COMBINATIONS FOR USE IN NEOPLASIA - The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., breast cancer) by increasing DNA damage and reducing base excision repair (BER). | 06-23-2011 |
20110230564 | ANT4 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - The invention relates to methods for inducing male contraception and to methods of treating cell proliferation related disorders or diseases, such as cancer. The invention further relates to pharmaceutical compositions for inducing male contraception and for treating cell proliferation related disorders or diseases. | 09-22-2011 |
20110275581 | NUCLEAR EXPORT INHIBITORS OF TOPOISOMERASE II ALPHA - A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase IIα and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo IIα have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II. | 11-10-2011 |
20120004284 | PDK INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - The invention relates to methods of treating or preventing acquired or congenital mitochondrial diseases or disorders, including treating cell proliferation related disorders or diseases, such as cancer. The invention further relates to pharmaceutical compositions for treating such disorders or diseases. | 01-05-2012 |
20120046246 | METHODS FOR TREATING OSTEOCLAST-RELATED DISEASE, COMPOUNDS AND COMPOSITIONS THEREOF - This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for such uses, and compositions thereof. | 02-23-2012 |
20120100227 | KINASE PROTEIN BINDING INHIBITORS - The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer. | 04-26-2012 |
20120107323 | KINASE PROTEIN BINDING INHIBITORS - The invention provides compounds capable of treating a subject suffering from or being susceptible to a cell proliferative disorder (especially, cancer), methods of identifying and using the compounds, pharmaceutical compositions and kits thereof. | 05-03-2012 |
20120142723 | ACE2 ACTIVATOR COMPOUNDS AND METHODS OF USE THEREOF - The invention relates to methods of treating cardiovascular and cardiopulmonary diseases and associated conditions, including hypertension. The invention further relates to pharmaceutical compositions for treating cardiovascular and cardiopulmonary diseases, especially hypertension, and lung injury. | 06-07-2012 |
20130079297 | KINASE PROTEIN BINDING INHIBITORS - The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer. | 03-28-2013 |
20130165417 | METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED DISORDERS - The invention relates to methods of treating cardiovascular and cardiopulmonary diseases and associated conditions, including hypertension. The invention further relates to pharmaceutical compositions for treating cardiovascular and cardiopulmonary diseases, especially hypertension, and lung injury. | 06-27-2013 |
20130189257 | USE OF PKC-IOTA INHIBITORS FOR THE TREATMENT OF BREAST CANCER - The subject invention pertains to uses of PKC-iota inhibitors for treatment of breast cancer. In one embodiment, the subject invention provides novel uses of 1H-imidazole-4-carboxamide, 5-amino-1-[2,3 -dihydroxy-4-[(phosphonooxy) methyl]cyclopentyl]-,[1R-(1α, 2β, 3β, 4α)] (ICA-1) and related compounds for treatment of breast cancer. The compounds of the subject invention have potent anti-proliferative effects against human breast cancer cells. The compounds of the subject invention also inhibit the phosphorylation of IKK-α/IKK-β, induce chromatin condensation, and/or induce DNA fragmentation in cancer cells. | 07-25-2013 |
20130281389 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA - Topoisomerase II alpha (topo IIα) is exported from the cell nucleus in human myeloma cells by a chromosome-maintenance protein-1 (CRM1)-dependent mechanism, resulting in topo II inhibitor resistance. The nuclear export signal (NES) of topo IIα is unique, making it a potential target for small molecule inhibitors. Small molecules NES inhibitors were identified, which inhibited binding of topo IIα to the export receptor CRM1. Inhibition was specific to topo IIα as p53 trafficking was unaffected along with topo IIα protein expression and function (decatenation). These topo IIα-specific nuclear export inhibitors may potentially lead to a new approach in circumventing drug resistance in multiple myeloma. The compounds provide a protocol for treating multiple myeloma or an oncogenic disease. Further, the topoisomerase II nuclear export signal inhibitor may be combined with a topoisomerase II inhibitor. | 10-24-2013 |